Norway closes our Nordic RWD series for a reason.
A universal healthcare system, personal identifiers, and decades of national coverage enable true longitudinal follow-up across care settings.
This is not just data availability.
It is data continuity.
Core Norwegian RWD pillars include:
▶️NorPD – complete outpatient prescription data
▶️ Norwegian Patient Registry – nationwide specialist care
▶️ Norwegian Registry for Primary Health Care – nationwide primary care data
▶️ Cancer Registry of Norway – high-quality oncology outcomes
▶️ Population surveys and biobanks – clinical, biological and lifestyle linkage
▶️ EHR systems – increasingly accessible under strict governance frameworks
Together, these sources support:
✅ Treatment pathway reconstruction
✅ Population-scale safety and utilisation analyses
✅ External control arms and trial emulation
✅ RWE aligned with regulatory and HTA decision-making
Across the Nordics, we see strong RWD ecosystems.
Norway stands out for the depth of longitudinal linkage across the full patient journey.
It illustrates what sustained investment in registries and trust-based governance can enable for life science research.
Where do you see the strongest use case for Norwegian RWE today?